睿知中国医院研究地图
候选清单

即将招募淋巴瘤II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由天津医科大学肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07944651,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. 3. Received at least one prior line of systemic therapy containing a covalent BTK-inhibitor.

    入选标准第 3 条

    11.For females of child-bearing potential, two negative pregnancy tests (at least one serum pregnancy test) are required prior to treatment initiation. The first test must be performed 10-14 days before the first dose of sonrotoclax; the second test must be performed within 24 hours before the first dose of sonrotoclax.

    入选标准第 17 条

    2. Prior treatment with a BCL-2 inhibitor or pirtobrutinib.

    排除标准第 2 条

    3. Major surgery within 4 weeks prior to screening. Note: If a subject has undergone major surgery, they must have fully recovered from any toxicities and/or complications of the intervention before receiving the first dose of study drug.

    排除标准第 3 条

    4. History of other active malignant disease within 2 years before entering the study, with the following exceptions: (1) adequately-treated carcinoma in-situ of the cervix; (2) localized basal-cell or squamous-cell skin carcinoma; (3) previously-diagnosed malignancy that has been controlled with curative-intent local treatment (surgery or other modalities).

    排除标准第 4 条

    Subjects who are hepatitis B core antibody (HBcAb)-positive and hepatitis B surface antigen (HBsAg)-negative must have a negative HBV-PCR result prior to the first study-drug dose. Subjects who are HBsAg-positive or HBV-DNA-positive are excluded.

    排除标准第 7 条

  3. 6.Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

    入选标准第 6 条

  4. Absolute neutrophil count (ANC) ≥ 1 × 10⁹/L without growth-factor support within 7 days prior to testing;

    入选标准第 8 条

    Platelet count ≥ 75 × 10⁹/L, or ≥ 50 × 10⁹/L in the setting of bone-marrow involvement; no growth-factor support or transfusion within 7 days prior to testing.

    入选标准第 9 条

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN);

    入选标准第 11 条

    Total bilirubin ≤ 2 × ULN, except for subjects with confirmed Gilbert syndrome, in whom bilirubin up to 5 × ULN is permitted.

    入选标准第 12 条

    Creatinine clearance ≥ 60 mL/min (estimated by the Cockcroft-Gault formula, or eGFR calculated using the Modification of Diet in Renal Disease [MDRD] formula);

    入选标准第 14 条

    Serum creatinine ≤ 1.5 × ULN.

    入选标准第 15 条

    10.International normalized ratio (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.

    入选标准第 16 条

  5. 5.Presence of at least one measurable lesion. Measurable disease is defined as a tumor mass ≥ 1.5 cm in one or two dimensions; splenic lesions are considered measurable.

    入选标准第 5 条

  6. 6. Known human immunodeficiency virus (HIV) infection, or serology suggestive of active hepatitis B or hepatitis C infection, as follows:

    排除标准第 6 条

    Subjects with positive hepatitis C antibody must have a negative HCV-RNA result before the first dose of study drug. Subjects with positive HCV-PCR are excluded.

    排除标准第 8 条

  7. 12.Females of child-bearing potential must agree to use two reliable contraceptive methods (one highly-effective method plus one additional effective method), starting 4 weeks prior to initiating sonrotoclax, throughout study participation, and for at least 90 days after the last dose of pirtobrutinib or 12 months after the last dose of rituximab (whichever is longer). Highly-effective contraception includes abstinence, hysterectomy, bilateral oophorectomy with 6-month amenorrhea, intrauterine system, and hormonal contraception (e.g., injectable or oral contraceptives). Male subjects must be vasectomized or use barrier contraception while their female partners employ effective contraception as described above. Male subjects must refrain from sperm donation during the study and for at least 90 days after the last dose of pirtobrutinib and sonrotoclax, or for 12 months after the last dose of rituximab (whichever is longer).

    入选标准第 18 条

    16. Pregnant or breastfeeding women.

    排除标准第 24 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07944651,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 1.Histopathologically-confirmed mantle cell lymphoma (MCL) with documented t(11;14)(q13;q32) translocation and/or cyclin-D1 over-expression, accompanied by relevant biomarkers (e.g., CD5, CD19, CD20, or PAX5). All subjects must provide sufficient archived or fresh tumor tissue samples for immunohistochemistry (IHC) testing.
  2. 2.Age ≥ 18 years, male or female.
  3. 3. Received at least one prior line of systemic therapy containing a covalent BTK-inhibitor.
  4. 4.Histopathologically-confirmed high-risk MCL, defined as meeting at least one of the following criteria: POD24, complex karyotype, TP53 mutation, del(17p), high-risk MIPI score, blastoid / pleomorphic variant, Ki-67 ≥ 30 %, bulky disease.
  5. 5.Presence of at least one measurable lesion. Measurable disease is defined as a tumor mass ≥ 1.5 cm in one or two dimensions; splenic lesions are considered measurable.
  6. 6.Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  7. 7.Adequate hematological function:
  8. Absolute neutrophil count (ANC) ≥ 1 × 10⁹/L without growth-factor support within 7 days prior to testing;
  9. Platelet count ≥ 75 × 10⁹/L, or ≥ 50 × 10⁹/L in the setting of bone-marrow involvement; no growth-factor support or transfusion within 7 days prior to testing.
  10. 8.Adequate hepatic function:
  11. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN);
  12. Total bilirubin ≤ 2 × ULN, except for subjects with confirmed Gilbert syndrome, in whom bilirubin up to 5 × ULN is permitted.
  13. 9.Adequate renal function:
  14. Creatinine clearance ≥ 60 mL/min (estimated by the Cockcroft-Gault formula, or eGFR calculated using the Modification of Diet in Renal Disease [MDRD] formula);
  15. Serum creatinine ≤ 1.5 × ULN.
  16. 10.International normalized ratio (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
  17. 11.For females of child-bearing potential, two negative pregnancy tests (at least one serum pregnancy test) are required prior to treatment initiation. The first test must be performed 10-14 days before the first dose of sonrotoclax; the second test must be performed within 24 hours before the first dose of sonrotoclax.
  18. 12.Females of child-bearing potential must agree to use two reliable contraceptive methods (one highly-effective method plus one additional effective method), starting 4 weeks prior to initiating sonrotoclax, throughout study participation, and for at least 90 days after the last dose of pirtobrutinib or 12 months after the last dose of rituximab (whichever is longer). Highly-effective contraception includes abstinence, hysterectomy, bilateral oophorectomy with 6-month amenorrhea, intrauterine system, and hormonal contraception (e.g., injectable or oral contraceptives). Male subjects must be vasectomized or use barrier contraception while their female partners employ effective contraception as described above. Male subjects must refrain from sperm donation during the study and for at least 90 days after the last dose of pirtobrutinib and sonrotoclax, or for 12 months after the last dose of rituximab (whichever is longer).
  19. 13.Estimated life expectancy > 3 months.
  20. 14.Capable of providing written informed consent, and able to understand and comply with study requirements.

排除标准:Exclusion Criteria:

  1. 1. Current or suspected central nervous system (CNS) involvement of mantle cell lymphoma, or a prior history of CNS-involved disease.
  2. 2. Prior treatment with a BCL-2 inhibitor or pirtobrutinib.
  3. 3. Major surgery within 4 weeks prior to screening. Note: If a subject has undergone major surgery, they must have fully recovered from any toxicities and/or complications of the intervention before receiving the first dose of study drug.
  4. 4. History of other active malignant disease within 2 years before entering the study, with the following exceptions: (1) adequately-treated carcinoma in-situ of the cervix; (2) localized basal-cell or squamous-cell skin carcinoma; (3) previously-diagnosed malignancy that has been controlled with curative-intent local treatment (surgery or other modalities).
  5. 5. Active, uncontrolled systemic fungal, bacterial, or viral infection (defined as persistent signs/symptoms related to infection with no improvement despite appropriate antibiotic, antiviral, and/or other therapy).
  6. 6. Known human immunodeficiency virus (HIV) infection, or serology suggestive of active hepatitis B or hepatitis C infection, as follows:
  7. Subjects who are hepatitis B core antibody (HBcAb)-positive and hepatitis B surface antigen (HBsAg)-negative must have a negative HBV-PCR result prior to the first study-drug dose. Subjects who are HBsAg-positive or HBV-DNA-positive are excluded.
  8. Subjects with positive hepatitis C antibody must have a negative HCV-RNA result before the first dose of study drug. Subjects with positive HCV-PCR are excluded.
  9. 7. Clinically significant cardiovascular disease, including:
  10. Myocardial infarction within 6 months before screening;
  11. Unstable angina within 3 months before screening;
  12. Clinically significant arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes);
  13. QTcF (Fridericia correction) > 480 msec;
  14. History of second-degree type-II or third-degree atrioventricular (AV) block;
  15. New York Heart Association (NYHA) class III or IV congestive heart failure.
  16. 8. History of severe bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring transfusion or other medical intervention.
  17. 9. History of deep-vein thrombosis (DVT) or pulmonary embolism (PE) within the previous 12 months.
  18. 10. History of a major cerebrovascular event (including stroke or intracranial hemorrhage) within 6 months before the first dose of study drug.
  19. 11. Requiring ongoing treatment with strong or moderate CYP3A inhibitors or CYP3A inducers. Subjects who have received strong/moderate CYP3A inhibitors or inducers within 7 days (or less than 5 drug half-lives) before the first study-drug dose are excluded. Subjects receiving moderate CYP3A inhibitors may be considered for enrollment after a minimum 7-day wash-out period.
  20. 12. Requiring anticoagulation with warfarin or an equivalent vitamin-K antagonist (e.g., phenprocoumon) within 7 days of the first study-drug dose.
  21. 13. Active bleeding gastrointestinal ulcer, except cases attributable to mantle-cell lymphoma identified on endoscopy.
  22. 14. Known hypersensitivity to urate-lowering agents.
  23. 15. History of toxic epidermal necrolysis or Stevens-Johnson syndrome.
  24. 16. Pregnant or breastfeeding women.
  25. 17. Known hypersensitivity to any of the study drugs.
  26. 18. Any psychiatric or cognitive disorder that may limit the subject's ability to understand, provide informed consent, or comply with study requirements.
  27. 19. Subjects with active drug or alcohol abuse. Any life-threatening disease, medical condition, or organ-system dysfunction that, in the investigator's judgment, may jeopardize subject safety or introduce additional risks to participation in the study.

引自 ClinicalTrials.gov, NCT07944651, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07944651,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07944651